Search
TORL-2-307
go.drugbank.com/drugs/DB18376ExperimentalTORL-2307 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against claudin 18.2 (CLDN18.2) being investigated for the treatment of gastric and pancreatic cancer.
Ozekibart
go.drugbank.com/drugs/DB18675InvestigationalOzekibart is a tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5). It is being investigated for the treatment of chondrosarcoma.
Pamapimod
go.drugbank.com/drugs/DB19169InvestigationalPamapimod is under investigation in clinical trial NCT05659459 (The KIN-FAST Trial (KIN001 for Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With Sars-cov-2).
Tigozertinib
go.drugbank.com/drugs/DB19239InvestigationalTigozertinib (BLU-945) is currently under investigation in clinical trial NCT04862780 (Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC) for the treatment of NSCLC.
D-1,4-dithiothreitol
go.drugbank.com/drugs/DB02184ExperimentalA reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH (thiol) groups and for reducing disulphides to dithiols. [PubChem]
CTA30X UCAR-T
go.drugbank.com/drugs/DB24819InvestigationalCTA30X UCAR-T is a biologic drug. CTA30X UCAR-T is under investigation in clinical trial NCT05015972 (UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies).
ND7001
go.drugbank.com/drugs/DB05142ExperimentalND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. … Known drug targets of ND7001 including phosphodiesterase 2A, cGMP-stimulated and cGMP-dependent 3',5'-cyclic phosphodiesterase. It is a new type of antidepressant drug with anxiolytic activity.
Azidocillin
go.drugbank.com/drugs/DB08795ExperimentalAzidocillin is a penicillin antibiotic similir to ampicillin.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseLesopitron
go.drugbank.com/drugs/DB04970ExperimentalLesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.
SR 121463
go.drugbank.com/drugs/DB05455InvestigationalIt is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH). … SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype.